文档介绍：• HIV testing: HIV antibody testing should be offered to all HBV-
HIGHLIGHTS OF PRESCRIBING INFORMATION infected patients before initiating therapy with VIREAD. VIREAD
These highlights do not include all the information needed to use should only be used as part of an appropriate antiretroviral
VIREAD safely and effectively. See full prescribing information combination regimen in HIV-infected patients with or without HBV
for VIREAD. coinfection. ()
VIREAD® (tenofovir disoproxil fumarate) tablets • Decreases in bone mineral density (BMD): Observed in HIV-
infected patients. Consider assessment of BMD in patients with a
Initial . Approval: 2001 history of pathologic fracture or other risk factors for osteoporosis
or bone loss. ()
WARNINGS: LACTIC ACIDOSIS/SEVERE HEPATOMEGALY
WITH STEATOSIS and POST TREATMENT EXACERBATION OF
• Redistribution/accumulation of body fat: Observed in HIV-infected
HEPATITIS
patients receiving antiretroviral combination therapy. ()
See full prescribing information for complete boxed warning. • Immune reconstitution syndrome: Observed in HIV-infected
patients. May necessitate further evaluation and treatment. ()
• Lactic acidosis and severe hepatomegaly with steatosis,
including fatal cases, have been reported with the use of • Triple n